bit.bio
bit.bio expands human heart cell portfolio through myriamed partnership
September 30, 2026Biotechnology, bit.bio, drug discovery, myriamed, safety testing
bit.bio has partnered with German biotechnology company myriamed to offer cryopreserved human induced pluripotent stem cell (iPSC)-derived cardiomyocytes for drug …
Bit.bio announces cell therapy pipeline
November 8, 2023Medical Communications Hepatology, bit.bio, cell therapy, liver failure
Bit.bio has announced its cell therapy pipeline as well as having shared its lead cell therapy candidate, preparing to enter …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
